GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Gabapentin immediate-release (Neurontin)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Immediate-release gabapentin only. Do not apply this table to Horizant or Gralise. Source summary and reproduced table use different boundary notation.

Check source scope before reading a dose

GlobalRPh RX List - Neurontin

Product / population
Immediate-release gabapentin; source renal table for age 12 years and older.
Renal method
CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source revision
Revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Documented differences and cautions on this drug

All record notes are retained here, including notes about sources not selected in this review.

Gabapentin formulations have different renal rules

Immediate-release gabapentin, GRALISE and HORIZANT are not interchangeable renal protocols. HORIZANT also has indication-specific schedules.

What to reconcile: Select the actual formulation and indication before using a dose or dialysis instruction.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

Exact-30 boundary not resolved by RX table wording

The RX table prints greater-than-30 to 59 and greater-than-15 to 29 bands; dialysis supplements are paired to maintenance regimens.

What to reconcile: Confirm the exact boundary and matched supplement in the complete current product table; no automatic dose calculation is provided.

Source difference identified; final patient-specific adjudication required.

Open this note and its source references

NEURONTIN: printed renal bands leave a boundary unclear

The RX table prints >30 to 59 and >15 to 29; exactly 30 is not clearly assigned. The hemodialysis supplement also belongs with a selected maintenance regimen.

What to reconcile: Verify the current table rather than silently rounding into a band. Do not select a supplement without its corresponding maintenance context.

Source-specific interpretation; independent clinician adjudication pending.

Open this note and its source references
Rxlist

GlobalRPh RX List - Neurontin

Open original reference

GlobalRPh-hosted RX List · Immediate-release gabapentin; source renal table for age 12 years and older.

Renal method: CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date: Revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Locally imported selected source sections; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Printed renal bandTotal daily doseSchedule
At least 60900-3,600 mg/dayThree divided doses
Greater than 30 to 59400-1,400 mg/dayTwo divided doses
Greater than 15 to 29200-700 mg/dayOnce daily
15100-300 mg/dayOnce daily

Below 15, reduce in proportion to CrCl. Hemodialysis requires renal-function-based maintenance plus a matched supplement after each four hours of dialysis; the specific five maintenance/supplement pairs must be selected from original Table 1 and are not collapsed into a free-standing supplement range here. The printed band wording leaves an exact-30 boundary ambiguity; no cutoff was guessed. Renal dosing below age 12 was not studied. Do not substitute extended-release regimens.

RDM33-rxlist-gabapentin-C1 · Source locator: Table 1 and footnotes a/b: renal function and hemodialysis.

Source-specific limits

Exact-30 printed boundary and matched dialysis supplement table require reference review.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/neurontin-drug/
Retrieved
2026-09-07
Renal-function method
CrCl by Cockcroft-Gault in stable renal function, mL/min.
Source date/version
Revision date not established in selected retrieval.
Hash meaning
SHA-256 of the local authored summary only; original HTML/PDF/SPL bytes are not bundled or hashed.
Local summary SHA-256
a24f0d37430035814a597321571838993111e7f00eeb71ec0b90133938a063ef

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=gabapentin&s1=RDM33-rxlist-gabapentin&h1=1712b5c4eb7f98b751d7ef1445e66e61de334b688f299cf40c7a722ce1862b99